Respected Wall Street analyst Dr Raghuram Selvaraju has published a research update on Cynata, reiterating the “buy” recommendation and price target of $1.50
Respected Wall Street analyst Dr Raghuram Selvaraju has published a research update on Cynata, reiterating the “buy” recommendation and price target of $1.50
Using our valuation model and taking into account the future revenues from its Cymerus™ platform, the company’s current total value should be AUD 150-175 million, or AUD 1.67-1.95 per share. This represents a substantial upside from the current share price
Respected Wall Street analyst Dr Raghuram Selvaraju has published new research on Cynata: “Raising price target—anticipating further milestones near-term. We believe that Cynata is entering a catalyst-rich period, with the possible option exercise near-term in its arrangement with Fujifilm...”
With 11 reasons to consider Cynata Therapeutics and an expected total share holder return of 331%, NDF sees a price target of $2.00 per share based on a probability-weighted valuation model.